A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Safety and Efficacy of Intravenous Iloprost in Subjects With Systemic Sclerosis Experiencing Symptomatic Digital Ischemic Episodes (AURORA Study)
Phase: PHASE3
Conditions: Raynaud's Phenomenon Secondary to Systemic Sclerosis
Sponsor: Civi Biopharma, Inc.



PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD